PALOMA-2 Trial Dashboard
Final OS results from the PALOMA-2 Phase 3 trial — palbociclib + letrozole vs placebo in ER+/HER2– advanced breast cancer. 90.1 months of median follow-up, OS of 53.9 vs 51.2 months. Dashboard includes a recovered data analysis module and FDA approval context for CDK4/6 inhibitors.
Challenge
The final OS results attracted attention partly because the difference was smaller than expected. Presenting that data honestly — including the recovered data analysis — without burying the nuance, and without making it look worse than it is, was the real challenge.
Solution
Clear visual comparisons across the ITT population breakdown, recovery analysis, and safety profile. Source DOIs are linked directly so users can check the numbers themselves. No spin, just the data laid out cleanly.
Role
Data Analyst
Year
2023